Other News To Note
Thursday, January 12, 2012
OctoPlus NV, of Leiden, the Netherlands, signed an agreement with a major pharmaceutical company based in the U.S. to explore the feasibility of a controlled-release formulation of a compound for delivery to the joints. Under the agreement, OctoPlus will develop the formulation using its PolyActive technology. If successful, there is potential for a development and manufacturing license agreement.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.